Cheap Cosmetic Testing Is Costing You Millions. Here’s the Math.

Most cosmetic brands want the same thing: faster launches, lower costs and stronger claims. But there is a costly mistake: choosing the cheapest available test and expecting it to support the biggest possible promise. The problem is not cheap testing. It is expecting evidence built for screening to prove outcomes it was never designed to measure.

What does “cheap” cosmetic testing actually deliver?

Low-cost testing provides valuable information during development. A package around £1,000 can determine whether a formulation remains stable, and whether it causes irritation under controlled conditions; however, such tests rarely demonstrate complex outcomes. They do not prove barrier improvement, microbiome restoration, reduced visible ageing or a clinically meaningful benefit.

Why do underpowered studies fail?

Claims require evidence that matches the promise. Many weak studies fail not because the study design cannot answer the question the claim requires. Problems often include small participant numbers, the absence of an appropriate control group, testing individual ingredients rather than the finished product, or extending conclusions beyond what was actually measured. The important thing is whether the evidence can withstand scrutiny from regulators, retailers and increasingly informed consumers.

What happens when a claim is challenged?

The cost of weak evidence is rarely limited to the testing fee. A challenged claim can require removal of advertising, delayed launches, additional studies and damage to retailer confidence. A £10,000 saving becomes a six-figure problem when a flagship claim fails.

How does multi-omics compare on a cost-per-claim basis?

Multi-omics is more expensive because it answers deeper questions: what changed, why it changed and whether those changes relate to consumer outcomes. For complex claims involving microbiome health or personalised skincare, it can strengthen evidence and reduce uncertainty. It does not replace clinical studies but helps explain the mechanisms behind observed effects.

What price range buys regulator-defensible evidence?

The right investment depends on the claim; there is no universal price for regulator-defensible evidence. Lower-risk claims may need only safety, stability and basic evaluation (£5,000–£20,000), while breakthrough claims involving microbiome modulation, anti-ageing or biological repair require stronger human evidence, objective measurements and potentially microbiome or biomarker analysis. Controlled human studies can start from £40,000.

Where can brands legitimately save?

Smart savings come from matching evidence investment to product risk. Brands can reduce unnecessary costs by using early screening approaches to refine formulations, eliminate weaker candidates before expensive studies begin, and focus deeper evidence generation on their most commercially important products. The mistake is spending less and expecting the evidence to prove more. The goal is to invest in the right evidence at the right stage.